image
Healthcare - Medical - Healthcare Information Services - NYSE - US
$ 24.16
-0.617 %
$ 1.42 B
Market Cap
-23.69
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PHR stock under the worst case scenario is HIDDEN Compared to the current market price of 24.2 USD, Phreesia, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PHR stock under the base case scenario is HIDDEN Compared to the current market price of 24.2 USD, Phreesia, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one PHR stock under the best case scenario is HIDDEN Compared to the current market price of 24.2 USD, Phreesia, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart PHR

image
$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.0$22.0$22.0$20.0$20.0$18.0$18.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
420 M REVENUE
17.83%
-58.1 M OPERATING INCOME
55.91%
-58.5 M NET INCOME
57.24%
32.4 M OPERATING CASH FLOW
200.01%
-24.1 M INVESTING CASH FLOW
39.28%
-11.5 M FINANCING CASH FLOW
32.89%
110 M REVENUE
2.70%
16.3 M OPERATING INCOME
217.53%
-6.39 M NET INCOME
55.63%
16.3 M OPERATING CASH FLOW
181.00%
-7.06 M INVESTING CASH FLOW
-68.77%
-6.63 M FINANCING CASH FLOW
-301.51%
Balance Sheet Phreesia, Inc.
image
Current Assets 203 M
Cash & Short-Term Investments 84.2 M
Receivables 103 M
Other Current Assets 16.3 M
Non-Current Assets 185 M
Long-Term Investments 0
PP&E 26.1 M
Other Non-Current Assets 159 M
21.68 %26.46 %4.19 %6.72 %40.95 %Total Assets$388.4m
Current Liabilities 114 M
Accounts Payable 5.62 M
Short-Term Debt 0
Other Current Liabilities 108 M
Non-Current Liabilities 9.58 M
Long-Term Debt 8.8 M
Other Non-Current Liabilities 788 K
4.55 %87.70 %7.12 %Total Liabilities$123.6m
EFFICIENCY
Earnings Waterfall Phreesia, Inc.
image
Revenue 420 M
Cost Of Revenue 135 M
Gross Profit 285 M
Operating Expenses 343 M
Operating Income -58.1 M
Other Expenses 430 K
Net Income -58.5 M
450m450m400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00(50m)(50m)(100m)(100m)420m(135m)285m(343m)(58m)(430k)(59m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
67.86% GROSS MARGIN
67.86%
-13.84% OPERATING MARGIN
-13.84%
-13.94% NET MARGIN
-13.94%
-22.10% ROE
-22.10%
-15.07% ROA
-15.07%
-22.20% ROIC
-22.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Phreesia, Inc.
image
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)20192019202020202021202120222022202320232024202420252025
Net Income -58.5 M
Depreciation & Amortization 27.9 M
Capital Expenditures -24.1 M
Stock-Based Compensation 67 M
Change in Working Capital -6.49 M
Others 7.88 M
Free Cash Flow 8.29 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Phreesia, Inc.
image
Wall Street analysts predict an average 1-year price target for PHR of $32 , with forecasts ranging from a low of $30 to a high of $35 .
PHR Lowest Price Target Wall Street Target
30 USD 24.17%
PHR Average Price Target Wall Street Target
32 USD 32.45%
PHR Highest Price Target Wall Street Target
35 USD 44.87%
Price
Max Price Target
Min Price Target
Average Price Target
3636343432323030282826262424222220201818May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Phreesia, Inc.
image
Sold
0-3 MONTHS
6.28 M USD 7
3-6 MONTHS
4.05 M USD 8
6-9 MONTHS
1.51 M USD 9
9-12 MONTHS
278 K USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Wall Street Analysts Think Phreesia (PHR) Could Surge 28.02%: Read This Before Placing a Bet The consensus price target hints at a 28% upside potential for Phreesia (PHR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com - 2 weeks ago
Phreesia Maintains Its Momentum Phreesia remains resilient, maintaining guidance and showing strong financial performance, with Q4 revenue growth of 15% year-over-year and improved cash flow. Despite a slight deceleration in customer growth, Phreesia's revenue per healthcare services client increased, driven by network solutions, and the company expects 13.6% revenue growth in fiscal 2026. Future growth drivers include patient education initiatives and Post-Script Engagement, while competition is seen as beneficial, enhancing market awareness and adoption of healthcare solutions. seekingalpha.com - 1 month ago
Phreesia Named to G2's List of 2025 Best Healthcare Software Products ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia has been named to G2's 2025 Best Software Awards in the Best Healthcare Software Products category. businesswire.com - 1 month ago
Phreesia, Inc. (PHR) Q4 2025 Earnings Call Transcript Phreesia, Inc. (NYSE:PHR ) Q4 2025 Earnings Conference Call March 12, 2025 5:00 PM ET Company Participants Balaji Gandhi - CFO Chaim Indig - Co-Founder, CEO & Director Conference Call Participants Anne Samuel - JPMorgan Jessica Tassan - Piper Sandler Jailendra Singh - Triust Securities Ryan Daniels - William Blair Richard Close - Canaccord Genuity Ryan MacDonald - Needham & Company Jeff Garro - Stephens Daniel Grosslight - Citi Group Scott Schoenhaus - KeyBanc Capital Markets Operator Good evening, ladies and gentlemen, and welcome to Phreesia's Fourth Quarter Fiscal 2025 Earnings Conference Call. [Operator Instructions] First, I would like to introduce Balaji Gandhi, Phreesia's Chief Financial Officer. seekingalpha.com - 1 month ago
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates Phreesia (PHR) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.56 per share a year ago. zacks.com - 1 month ago
Phreesia Announces Fourth Quarter Fiscal 2025 Results ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2025. "We are pleased with our solid finish to fiscal 2025 and I am excited about the new products we have introduced over the past several quarters that improve medication adherence and the overall patient and provider experience," said CEO and Co-Founder Chaim Indig. Please visit the Phr. businesswire.com - 1 month ago
Phreesia (PHR) Moves 5.6% Higher: Will This Strength Last? Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 2 months ago
Phreesia's Sally Thayer Selected as a Top Woman Leader in Software ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia announced that Sally Thayer, VP of Product Management, is a winner for The Software Report's 2024 list of Top 50 Women Leaders in Software. businesswire.com - 2 months ago
Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2025 Results ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia will release its fiscal fourth quarter and fiscal year 2025 financial results after the close of market trading on Wednesday, March 12. businesswire.com - 2 months ago
Phreesia, Inc. (PHR) Soars to 52-Week High, Time to Cash Out? Phreesia (PHR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. zacks.com - 2 months ago
Zacks Industry Outlook Enovis, Omnicell and Phreesia Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article. zacks.com - 2 months ago
3 Medical Info Systems Stocks to Buy as Stargate AI Drives Industry Prospects Zacks Medical Info Systems industry stocks like Enovis, Omnicell and Phreesia are expected to gain from the GenAI wave. zacks.com - 2 months ago
8. Profile Summary

Phreesia, Inc. PHR

image
COUNTRY US
INDUSTRY Medical - Healthcare Information Services
MARKET CAP $ 1.42 B
Dividend Yield 0.00%
Description Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
Contact 434 Fayetteville Street, Raleigh, NC, 27601 https://www.phreesia.com
IPO Date July 18, 2019
Employees 2082
Officers Ms. Melissa Mitchell Chief Privacy Officer Mr. Evan Roberts Co-Founder & Chief Operating Officer Ms. Amy Beth VanDuyn Senior Vice President of Human Resources Ms. Allison C. Hoffman J.D. General Counsel & Secretary Ms. Maureen McKinney Vice President of Corporate Communications Mr. Jack Callahan Chief Technology Officer Ms. Yvonne Hui Vice President & Principal Accounting Officer Mr. Chaim Indig Co-Founder, Chief Executive Officer & Director Mr. David Linetsky Senior Vice President of Life Sciences Mr. Balaji Gandhi Chief Financial Officer